← Back to Search

Gene Expression Profiling

AlloMap Molecular testing for Heart Disease (EIMAGE Trial)

N/A
Waitlist Available
Research Sponsored by XDx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1.5 years
Awards & highlights

EIMAGE Trial Summary

This study is designed to evaluate the safety and efficacy of a peripheral blood mononuclear cell gene expression profiling method (AlloMap) in monitoring asymptomatic heart transplant patients for acute rejection beginning 2-6 months(≥ 55-185 days) after transplantation.

Eligible Conditions
  • Heart Disease
  • Transplant Rejection

EIMAGE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~enrollment and one year post transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and enrollment and one year post transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Event-Free Survival and intravascular ultrasound (IVUS) measures
Secondary outcome measures
Biopsy-related patient preferences satisfaction using a non-validated survey
Gene expression profiling scores and immunosuppressant doses
Number of biopsies performed.
+6 more

EIMAGE Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AlloMap Molecular testingExperimental Treatment1 Intervention
Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
Group II: Endomyocardial biopsyActive Control1 Intervention
Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection

Find a Location

Who is running the clinical trial?

XDxLead Sponsor
4 Previous Clinical Trials
4,473 Total Patients Enrolled
Upen Patil, MDStudy DirectorXDx, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
New England Journal of MedicineJournal
Gene-expression Profiling for Rejection Surveillance After Cardiac Transplantation
Pham, Michael X., Jeffrey J. Teuteberg, Abdallah G. Kfoury, Randall C. Starling, Mario C. Deng, Thomas P. Cappola, Andrew Kao, et al.. 2010. “Gene-expression Profiling for Rejection Surveillance After Cardiac Transplantation”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa0912965.
American Journal of TransplantationJournal
Noninvasive Discrimination of Rejection in Cardiac Allograft Recipients Using Gene Expression Profiling
Deng, M. C., H. J. Eisen, M. R. Mehra, M. Billingham, C. C. Marboe, G. Berry, J. Kobashigawa, et al.. 2006. “Noninvasive Discrimination of Rejection in Cardiac Allograft Recipients Using Gene Expression Profiling”. American Journal of Transplantation. Wiley. doi:10.1111/j.1600-6143.2005.01175.x.
clinicaltrials.govStudy
A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation
2009. "A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00962377.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top